Under Waxman’s microscope
Executive Summary
Public health consequences of drug-resistant microbes will be examined Nov. 7 by the House Oversight and Government Reform Committee. Reports about methicillin-resistant Staphylococcus aureus have focused public attention on the issue and may provide impetus for federal legislation. Sens. Sherrod Brown, D-Ohio, and Orrin Hatch, R-Utah, introduced Oct. 31 an antimicrobial resistance bill that already is pending in the House (1"The Pink Sheet" Oct. 15, 2007, p. 9). The proposed law would improve "our grasp on resistance and ways to control it," notes Donald Peretz, president of the Infectious Diseases Society of America. IDSA has been urging Congress for several years to create incentives for the development of new drugs to fight microorganisms resistant to existing therapies...
You may also be interested in...
Antimicrobial Drug Reviews Would Need To Consider “Resistance” Under Bill
Impact on drug-resistant microbes would be a factor considered during the review of antimicrobial drug applications under legislation introduced in the House Sept. 27 by Reps. Jim Matheson, D-Utah, and Mike Ferguson, R-N.J
Are Trial Sponsors Treading On Investigators’ Toes In Decentralized Trials?
The Danish regulator’s experience with reviewing and inspecting decentralized elements in clinical trials highlights concerns around the blurring of lines that divide the roles and responsibilities of sponsors and trial investigators.
Nichi-Iko Aims To Regroup As It Enters Turnaround Process
Japan’s Nichi-Iko has formally entered a business turnaround alternative dispute resolution process that will see the company outline a business rehabilitation plan involving management restructuring and a fresh profit structure, following financial underperformance in the wake of recent quality issues.